125 related articles for article (PubMed ID: 8196677)
1. Chronic administration does not alter the accumulation of L-dopa into muscle.
Rose S; Jenner P; Marsden CD
Mov Disord; 1994 Mar; 9(2):167-72. PubMed ID: 8196677
[TBL] [Abstract][Full Text] [Related]
2. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
3. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
Deleu D; Sarre S; Ebinger G; Michotte Y
J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
[TBL] [Abstract][Full Text] [Related]
4. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
Rose S; Jenner P; Marsden CD
J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
[TBL] [Abstract][Full Text] [Related]
5. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
Rose S; Jenner P; Marsden CD
J Pharm Pharmacol; 1993 Aug; 45(8):725-30. PubMed ID: 7901371
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
7. Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats.
Andre MH; Grignon S; Bruguerolle B
Fundam Clin Pharmacol; 1996; 10(4):350-5. PubMed ID: 8871134
[TBL] [Abstract][Full Text] [Related]
8. The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.
Deleu D; Sarre S; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):576-81. PubMed ID: 8133901
[TBL] [Abstract][Full Text] [Related]
9. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Fine SA; Frohman LA
J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
[TBL] [Abstract][Full Text] [Related]
10. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels.
Ogawa A; Kanazawa M; Takayanagi M; Kitani Y; Shintaku H; Kohno Y
Brain Dev; 2008 Jan; 30(1):82-5. PubMed ID: 17590551
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis.
Deleu D; Sarre S; Ebinger G; Michotte Y
J Pharm Biomed Anal; 1993 Jul; 11(7):577-85. PubMed ID: 8399532
[TBL] [Abstract][Full Text] [Related]
12. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
[TBL] [Abstract][Full Text] [Related]
13. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
14. Caffeic acid improves the bioavailability of L-dopa in rabbit plasma.
Wang LH; Hsu KY; Uang YS; Hsu FL; Yang LM; Lin SJ
Phytother Res; 2010 Jun; 24(6):852-8. PubMed ID: 19941381
[TBL] [Abstract][Full Text] [Related]
15. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
16. Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-dopa.
Brannan T; Knott P; Kaufmann H; Leung L; Yahr M
J Neural Transm; 1989; 75(2):149-57. PubMed ID: 2918307
[TBL] [Abstract][Full Text] [Related]
17. Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration.
Raftopoulos C; Dethy S; Laute MA; Goldman S; Naini AB; Przedborski S; Hildebrand J
Mov Disord; 1996 Jan; 11(1):59-62. PubMed ID: 8771068
[TBL] [Abstract][Full Text] [Related]
18. In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Nakashima M; Zhao MF; Nakashima MN; Sakurai M; Sasaki H; Matsuyama K; Ichikawa M
Biol Pharm Bull; 1996 Jul; 19(7):988-94. PubMed ID: 8839975
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.
Kim TK; Kang W; Chun IK; Oh SY; Lee YH; Gwak HS
Eur J Pharm Sci; 2009 Dec; 38(5):525-32. PubMed ID: 19804823
[TBL] [Abstract][Full Text] [Related]
20. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
